Nifty
:
24383.60
Sensex
:
78094.64
66.45 (0.27%)
166.49 (0.21%)
Nifty
Sensex
:
:
24383.60
78094.64
66.45 (0.27%)
166.49 (0.21%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
57/99

BSE: 532523 | NSE: BIOCON

NSE BSE
425.70
31-Jul-2026
  • Open
  • High
  • Low
  • Previous Close
  •  425.95
  •  428.25
  •  422.9
  •  425.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2304756
  •  981056381.95
  •  447.15
  •  331

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 69,367.93
  • 179.90
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 80,999.03
  • 0.12%
  • 2.05

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.68%
  • 6.15%
  • 10.26%
  • FII
  • DII
  • Others
  • 8.14%
  • 21.89%
  • 8.88%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.84
  • 15.64
  • 4.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.65
  • 17.49
  • 0.89

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -4.52
  • -9.87
  • -27.75

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 61.06
  • 61.66
  • 55.86

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.08
  • 2.79
  • 1.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.88
  • 16.04
  • 14.69

Earnings Forecasts:

(Updated: 01-08-2026)
Description
2026
2027
2028
2029
Adj EPS
61
1
76.66
3.83
P/E Ratio
6.98
425.70
5.55
111.15
Revenue
53.13
34.99
30.63
16989.1
EBITDA
19976.1
22816.9
24781.4
3416.01
Net Income
4418.06
5306.74
5871.8
653.52
ROA
1243.04
1861.47
2085.13
0.93
P/B Ratio
0.05
0.06
0.05
2.29
ROE
1.79
1.7
1.71
2.44
FCFF
3.66
5.28
5.57
302.1
FCFF Yield
2042.3
2655.18
2575.8
0.37
Net Debt
2.48
3.22
3.13
10798.7
BVPS
9247.55
7310.65
7854.2
185.91

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
4,516.60
4,417.00
2.25%
4,173.00
3,821.40
9.20%
4,295.50
3,590.40
19.64%
3,941.90
3,432.90
14.83%
Expenses
3,496.30
3,338.80
4.72%
3,339.50
3,069.60
8.79%
3,460.10
2,905.00
19.11%
3,193.00
2,812.50
13.53%
EBITDA
1,020.30
1,078.20
-5.37%
833.50
751.80
10.87%
835.40
685.40
21.89%
748.90
620.40
20.71%
EBIDTM
22.59%
24.41%
19.97%
19.67%
19.45%
19.09%
19.00%
18.07%
Other Income
52.50
36.90
42.28%
117.30
34.80
237.07%
93.00
32.50
186.15%
79.70
1,134.50
-92.97%
Interest
231.50
212.40
8.99%
209.90
223.40
-6.04%
272.20
225.60
20.66%
276.70
236.00
17.25%
Depreciation
513.40
436.30
17.67%
515.30
425.40
21.13%
473.00
419.90
12.65%
455.00
405.40
12.23%
PBT
247.50
486.80
-49.16%
-67.80
155.90
-
171.30
98.40
74.09%
96.90
1,145.50
-91.54%
Tax
48.90
27.40
78.47%
-16.00
74.80
-
38.50
71.30
-46.00%
7.70
283.70
-97.29%
PAT
198.60
459.40
-56.77%
-51.80
81.10
-
132.80
27.10
390.04%
89.20
861.80
-89.65%
PATM
4.40%
10.40%
-1.24%
2.12%
3.09%
0.75%
2.26%
25.10%
EPS
0.78
2.87
-72.82%
1.08
0.21
414.29%
0.63
-0.13
-
0.23
5.49
-95.81%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
-
16,927.00
15,261.70
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
Net Sales Growth
-
10.91%
3.43%
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
 
Cost Of Goods Sold
-
5,690.70
5,197.50
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
Gross Profit
-
11,236.30
10,064.20
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
GP Margin
-
66.38%
65.94%
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
Total Expenditure
-
13,585.40
12,243.00
11,559.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,469.00
3,039.90
Power & Fuel Cost
-
426.40
377.90
388.90
414.80
316.40
270.30
246.10
239.80
189.00
156.40
% Of Sales
-
2.52%
2.48%
2.64%
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
Employee Cost
-
3,508.00
3,144.40
2,664.10
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
% Of Sales
-
20.72%
20.60%
18.05%
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
Manufacturing Exp.
-
1,796.20
1,655.90
2,376.90
1,917.20
1,243.50
1,019.20
864.60
721.20
510.40
519.80
% Of Sales
-
10.61%
10.85%
16.11%
17.16%
15.19%
14.27%
13.72%
13.08%
12.38%
13.36%
General & Admin Exp.
-
1,065.90
948.10
806.00
359.60
181.50
270.50
182.10
53.00
56.80
21.70
% Of Sales
-
6.30%
6.21%
5.46%
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
Selling & Distn. Exp.
-
698.80
649.90
296.60
221.60
243.80
235.90
266.30
277.50
98.20
107.40
% Of Sales
-
4.13%
4.26%
2.01%
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
Miscellaneous Exp.
-
399.40
269.30
128.60
297.40
107.70
60.40
36.10
37.20
47.40
107.40
% Of Sales
-
2.36%
1.76%
0.87%
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
EBITDA
-
3,341.60
3,018.70
3,196.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
654.40
851.20
EBITDA Margin
-
19.74%
19.78%
21.66%
18.97%
18.24%
18.23%
19.95%
20.38%
15.87%
21.88%
Other Income
-
456.20
1,355.80
967.50
768.10
690.30
605.20
507.50
414.30
380.90
285.40
Interest
-
990.30
897.40
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
Depreciation
-
1,956.70
1,687.00
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
PBT
-
850.80
1,790.10
1,621.00
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
Tax
-
79.10
457.20
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
Tax Rate
-
17.66%
24.23%
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
PAT
-
385.60
1,013.30
1,022.50
462.70
648.40
740.50
777.10
905.30
372.40
612.10
PAT before Minority Interest
-
368.80
1,429.40
1,297.80
643.00
771.60
846.20
899.80
1,002.60
453.10
688.10
Minority Interest
-
16.80
-416.10
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
PAT Margin
-
2.28%
6.64%
6.93%
4.14%
7.92%
10.37%
12.33%
16.42%
9.03%
15.73%
PAT Growth
-
-61.95%
-0.90%
120.99%
-28.64%
-12.44%
-4.71%
-14.16%
143.10%
-39.16%
 
EPS
-
2.37
6.22
6.27
2.84
3.98
4.54
4.77
5.56
2.29
3.76

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
34,031.80
21,644.00
19,783.70
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
Share Capital
810.50
600.30
600.30
600.30
600.30
600.00
600.00
300.00
300.00
100.00
Total Reserves
32,707.00
20,618.80
18,863.30
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
Non-Current Liabilities
12,404.30
16,493.30
15,119.80
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
Secured Loans
10,476.30
10,502.50
11,267.70
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
Unsecured Loans
270.00
1,902.90
1,664.70
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
Long Term Provisions
330.30
260.80
237.60
226.50
91.70
106.20
85.80
66.10
49.30
36.00
Current Liabilities
14,069.20
14,333.80
15,358.80
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
Trade Payables
6,772.10
6,548.70
6,272.00
3,842.00
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
Other Current Liabilities
3,059.30
3,965.70
6,481.20
1,814.90
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
Short Term Borrowings
3,566.30
3,454.70
2,149.20
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
Short Term Provisions
671.50
364.70
456.40
373.60
292.30
261.80
230.90
204.30
135.60
143.20
Total Liabilities
63,095.00
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
Net Block
36,485.90
31,963.30
30,643.60
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
Gross Block
48,079.20
40,804.30
37,930.10
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
Accumulated Depreciation
11,593.30
8,841.00
7,286.50
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
Non Current Assets
45,915.20
42,253.40
40,574.20
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
Capital Work in Progress
6,986.70
8,508.40
7,993.30
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
Non Current Investment
1,089.30
679.70
684.10
742.30
370.20
743.20
108.50
182.50
63.80
188.00
Long Term Loans & Adv.
973.80
870.80
892.50
683.20
483.80
436.40
402.00
335.80
437.20
319.70
Other Non Current Assets
379.50
231.20
360.70
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
Current Assets
17,179.80
16,286.20
15,179.20
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
Current Investments
689.80
447.30
315.60
1,326.50
1,217.70
1,213.00
857.60
829.30
611.40
1,065.00
Inventories
6,085.70
4,931.10
4,943.90
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
Sundry Debtors
5,986.80
5,487.90
6,230.60
3,573.20
2,058.20
1,517.20
1,223.70
1,291.80
1,063.90
883.20
Cash & Bank
3,193.60
4,120.20
2,258.70
2,400.10
1,747.50
2,049.20
998.60
1,057.20
1,322.80
1,044.30
Other Current Assets
1,223.90
382.70
334.40
334.10
1,060.70
954.40
809.20
678.60
428.00
419.90
Short Term Loans & Adv.
804.70
917.00
1,096.00
456.40
400.50
293.30
349.90
302.30
110.20
48.40
Net Current Assets
3,110.60
1,952.40
-179.60
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
Total Assets
63,095.00
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
1,994.00
4,061.20
2,953.90
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
PBT
447.90
1,886.60
1,525.20
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
Adjustment
2,920.90
1,711.20
2,356.20
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
Changes in Working Capital
-1,132.20
923.00
-635.20
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
Cash after chg. in Working capital
2,236.60
4,520.80
3,246.20
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-242.60
-459.60
-292.30
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,082.10
-234.10
-1,004.50
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
Net Fixed Assets
-236.40
-393.50
-323.20
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
Net Investments
-13,595.10
-2,064.10
-47.80
-3,990.70
132.70
-459.90
-859.70
105.90
-310.80
-79.30
Others
11,749.40
2,223.50
-633.50
-10,030.70
-1,547.10
-3,033.90
-1,443.60
-539.10
-195.30
-203.30
Cash from Financing Activity
-923.60
-1,854.00
-2,332.70
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
Net Cash Inflow / Outflow
-1,011.70
1,973.10
-383.30
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
Opening Cash & Equivalents
2,923.80
919.50
1,299.90
653.70
897.00
824.70
659.30
449.00
710.20
757.50
Closing Cash & Equivalent
2,111.50
2,923.80
919.50
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
206.76
176.73
162.11
146.53
68.53
62.27
54.97
50.17
42.59
39.74
ROA
0.61%
2.50%
2.41%
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
ROE
1.35%
7.03%
7.00%
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
ROCE
3.26%
7.43%
7.03%
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
Fixed Asset Turnover
0.38
0.39
0.41
0.48
0.77
0.74
0.78
0.85
0.73
0.89
Receivable days
122.96
139.43
119.85
91.14
79.19
69.67
72.86
77.96
86.05
74.35
Inventory Days
118.06
117.49
112.31
105.87
92.60
84.38
71.47
58.05
60.00
54.81
Payable days
427.20
450.17
376.86
271.55
209.62
230.92
81.60
81.98
87.98
78.68
Cash Conversion Cycle
-186.17
-193.26
-144.70
-74.54
-37.84
-76.87
62.74
54.04
58.07
50.48
Total Debt/Equity
0.44
0.84
0.81
1.01
0.60
0.58
0.40
0.40
0.44
0.48
Interest Cover
1.45
3.10
2.57
3.14
15.54
20.88
19.72
18.12
10.57
33.05

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Biocon’s arm secures Health Canada’s nod for Yesintek (ustekinumab) Autoinjector Pen
    29th Jul 2026, 14:10 PM

    This approval further strengthens the company’s portfolio of immunology products in Canada

    Read More
  • Biocon gets EMA’s nod for new drug product fill finish line for Semglee at Malaysia facility
    16th Jul 2026, 10:39 AM

    Supplies to Europe from this line are expected to begin from Q2FY27

    Read More
  • Mylan Inc. exits Biocon through Rs 3,679 crore open market deals
    15th Jul 2026, 14:30 PM

    Mylan Inc. has divested its entire 5.64% stake in Biocon

    Read More
  • Biocon’s partner secures multiple insulin contracts in Malaysia
    24th Jun 2026, 11:51 AM

    Duopharma Biotech has secured multiple insulin contracts from Ministry of Health, Malaysia, valued at over 225 million Malaysian ringgit

    Read More
  • Biocon acquires stake in Ampin C&I Power Twelve
    11th Jun 2026, 10:45 AM

    This acquisition aligns with the company’s renewable energy objectives, supporting the procurement of green energy and advancing its decarbonization goals

    Read More
  • Biocon’s arm gets nod from Health Canada for Micafungin for injection
    11th May 2026, 14:12 PM

    The approval will further strengthen the company’s integrated biosimilars and generics portfolio

    Read More
  • Biocon reports 63% fall in Q4 consolidated net profit
    8th May 2026, 14:05 PM

    The total consolidated income of the company increased by 2.59% at Rs 4,569.10 crore for Q4FY26

    Read More
  • USFDA completes Pre-License inspection at Biocon’s biosimilars site
    30th Apr 2026, 09:39 AM

    At the conclusion of the inspection, the USFDA issued a Form 483 with five observations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.